Inhibition of EGFR signaling: all mutations are not created equal.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 16288556.
- Also identified by PMC identifier 1479603.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Gazdar and Minna discuss the context and implications of a research article that examines the transformation potential and response to inhibitors of specific <i>EGFR</i> mutations found in lung cancer.
Medical subject headings
- ErbB Receptors
- Lung Neoplasms
- Protein-Tyrosine Kinases
- Signal Transduction